Author
Listed:
- Siyuan Fu
(Nanjing University of Posts and Telecommunications)
- Zhiyu Wang
(Nanjing University of Posts and Telecommunications)
- Peihong Huang
(Nanjing University of Posts and Telecommunications)
- Guanjun Li
(Nanjing University of Posts and Telecommunications)
- Jian Niu
(Nanjing University of Posts and Telecommunications)
- Zhiyang Li
(Nanjing University)
- Guangyue Zu
(Chinese Academy of Sciences)
- Pengcheng Zhou
(Affiliated Hospital of Nantong University)
- Lianhui Wang
(Nanjing University of Posts and Telecommunications)
- David Tai Leong
(National University of Singapore)
- Xianguang Ding
(Nanjing University of Posts and Telecommunications)
Abstract
Current myocardial infarction (MI) treatment strategies remain challenged in suboptimal pharmacokinetics and potential adverse effects. Here we present a bioelectronic interface capable of producing on-demand abundant bioactive extracellular vesicles (EVs) near the MI area for in-situ localized treatment. The technology, termed electroactive patch for wirelessly and controllable EV generation (ePOWER), leverages wireless bioelectronic patch to stimulate embedded electrosensitive macrophages, actively modulating the biosynthesis of EVs and enabling EV production with high programmability to be delivered directly to the MI area. ~2400% more bioactive EVs were produced per cell under our ePOWER system. When surgically implanted, we demonstrate the therapeutic potential of in-situ EV production system to alleviate MI symptoms and improve cardiac function. This programmable ePOWER technology enables in-situ production of therapeutically rich EVs, thus reducing the need for exogenous cell expansion platforms and dedicated delivery, holding promise as a therapeutic all-in-one platform to treat various diseases.
Suggested Citation
Siyuan Fu & Zhiyu Wang & Peihong Huang & Guanjun Li & Jian Niu & Zhiyang Li & Guangyue Zu & Pengcheng Zhou & Lianhui Wang & David Tai Leong & Xianguang Ding, 2025.
"Programmable production of bioactive extracellular vesicles in vivo to treat myocardial infarction,"
Nature Communications, Nature, vol. 16(1), pages 1-16, December.
Handle:
RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-58260-0
DOI: 10.1038/s41467-025-58260-0
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-58260-0. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.